Executive dysfunction using behavioral assessment of the dysexecutive syndrome in Parkinson's disease
โ Scribed by Satoshi Kamei; Motohiko Hara; Kan Serizawa; Masato Murakami; Tomohiko Mizutani; Motoko Ishiburo; Ritsuko Kawahara; Yukiko Takagi; Katsuhiko Ogawa; Hirokazu Yoshihashi; Satoru Shinbo; Yutaka Suzuki; Mai Yamaguchi; Akihiko Morita; Jun Takeshita; Kaname Hirayanagi
- Publisher
- John Wiley and Sons
- Year
- 2008
- Tongue
- English
- Weight
- 104 KB
- Volume
- 23
- Category
- Article
- ISSN
- 0885-3185
No coin nor oath required. For personal study only.
โฆ Synopsis
Abstract
The objective of this study was to evaluate the executive dysfunction (ExD) in Parkinson's disease (PD) using the Behavioral Assessment of the Dysexecutive Syndrome (BADS), which provides a wideโrange assessment of ExD. The BADS and the Unified Parkinson's Disease Rating Scale (UPDRS) were investigated in 63 nondemented PD patients who revealed scores of โฅ24 points on the MiniโMental State Examination based on the DSMโIV. Multiple logistic regression analysis was performed to evaluate the predisposing factors to ExD, which was defined as <70 points on the ageโcontrolled standardized score. The total score on the UPDRS was a significant independent predisposing factor to ExD. Among the various parts of the UPDRS, part II was the significant factor for ExD. The profile scores of all subtests on the BADS in patients with ExD were significantly lower than those of patients without ExD. All profile scores decreased with severity of PD, but the changes among these scores differed. ExD in nondemented PD predisposed to a greater severity of PD, particularly as regards the activity of daily living impairment. Nondemented PD revealed wideโrange components of ExD. All components of ExD were impaired with severity of PD, but the patterns of each component exhibited variety. ยฉ 2007 Movement Disorder Society
๐ SIMILAR VOLUMES
## Abstract We developed a questionnaire to assess autonomic symptoms in patients with Parkinson's disease (PD) and evaluated its reliability and validity. Based on the results of a postal survey in 46 PD patients, 21 multiple system atrophy patients, and 8 movement disorders specialists, items wer
## Abstract Executive dysfunction (ED) is a prominent and often disabling feature of cognitive impairment in Parkinson's disease (PD). Few studies have examined treatments. Given the role of noradrenergic pathology in ED, atomoxetine, a norepinephrine reuptake inhibitor indicated for attention defi
## Abstract ## Background Both executive cognitive dysfunction and behavioral problems contribute to dysexecutive symptoms in daily life. The aim of the present study was to develop a behavior rating scale for assessing dysexecutive symptoms in Japanese patients with AD. ## Method The Dysexecuti
## Abstract Objective measurements to assess the efficacy of rehabilitation treatment in Parkinson's disease, suitable to be carried out routinely in the clinical setting, are lacking. Metabolic parameters, reflecting the recruitment and coโordination of muscle fibers, might be simple instrumental
## Abstract To investigate the psychiatric symptoms accompanying the early phases of Parkinson's disease (PD), we injected adult rats with 10.5 ฮผg 6โhydroxydopamine (6โOHDA) bilaterally into the dorsal striatum. The resulting neurodegeneration led, 12 weeks after injection, to a mild (36%) reductio